Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma

Trial Profile

Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 11 Sep 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 01 May 2018 Planned End Date changed from 1 Apr 2025 to 1 Aug 2025.
    • 01 May 2018 Planned primary completion date changed from 1 Apr 2024 to 1 Aug 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top